



EFFECTIVE DATE: 09/04/2007
POLICY LAST UPDATED: 10/15/2013

OVERVIEW

In vitro chemoresistance and chemosensitivity assays have been investigated as a means of predicting tumor response to various chemotherapies. These assays have been used by oncologists to select chemotherapy regimens for an individual patient.

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHIP for Medicare and Commercial Products:

In vitro chemosensitivity assays and chemoresistance assays are considered not medically necessary as there have been no prospective clinical trials that have demonstrated improved survival among patients in whom chemosensitivity or chemoresistance assays were used to positively select or exclude chemotherapy regimens.

MEDICAL CRITERIA

Not applicable

BACKGROUND

In vitro chemoresistance and chemosensitivity assays have been investigated as a means of predicting tumor response to various chemotherapies. Thus these assays have been used by oncologists to select chemotherapy regimens for an individual patient. A variety of assays have been developed that differ in their processing and in the technique used to measure the sensitivity or resistance. However, all involve the same four basic steps: 1) isolation of cells, 2) incubation of cells with drugs, 3) assessment of cell survival, and 4) interpretation of the result. A variety of techniques have been evaluated to assess cell survival, including the differential staining cytotoxicity (DiSC®) assay, the thymidine incorporation assay, fluorescence (cytoprint) assays, and the MTT assay.

Results may be reported as either drug sensitive, drug resistant, or intermediate. Drugs identified as drug sensitive are thought to be potentially effective in in-vitro chemotherapy, while drugs identified as resistant are thought to be potentially ineffective chemotherapies. Chemoresistance is the one most commonly used.

Evidence is insufficient as larger studies and prospective trials are still needed to assess the impact of testing on treatment decisions and health outcomes. -

COVERAGE

Benefits vary between groups/contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for applicable surgery services and services not medically necessary coverage.

CODING

There is no specific CPT code for these assays as the extreme drug resistance assay is a multistep laboratory procedure that might be identified by several codes. Claims should be filed with an unlisted code

RELATED POLICIES

None

PUBLISHED

Provider Update	Dec 2013
Provider Update	May 2012
Provider Update	Aug 2012
Provider Update	Sep 2011
Provider Update	Nov 2010
Provider Update	Oct 2009
Provider Update	Oct 2008

REFERENCES

Blue Cross Blue Shield Association Medical Policy Reference. Policy 2.03.01 - In Vitro Chemoresistance and Chemosensitivity Assays.

Cree IA, Kurbacher CM, Lamont A, et al. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. *Anticancer Drugs*; 2007;18(9):1093-1101.

Iwadate Y, Sakaida T, Saegusa T, Hiwasa T, Takiguchi M, Fujimoto S, Yamaura A. Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. *International Journal of Oncology*; 2005;26(4):993-998.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

